239 / 1138
•
–
SBRT improved OS compared with CFRT regardless of chemotherapy
use in this population-based analysis of clinical stage I NSCLC
National Cancer Database (1998-2010)
Stage I NSCLC (
5,944 SBRT, 13,429 CFRT)
Robinson C. proc ASCO 2015 abstr 7513
Median OS
32.3
vs.
25.6
months
p<0.001
Median OS
29.8
vs.
26.2
months
p<0.001
All patients
No chemotherapy
Months
Survival
1.0
0.75
0.50
0.25
0.0
0 12 24 36 48 60 72 84 96 108
Survival
1.0
0.75
0.50
0.25
0.0
0 12 24 36 48 60 72 84 96 108
Conventional
SBRT
Conventional
SBRT
Months